Dr. A. John Rush Jr.

• 
  www.projectsinknowledge.com/cp/index.cfm?jn=1830&thspag - [Cached Version]
  Published on: 5/18/2009    Last Visited: 5/18/2009  

  A. John Rush, MD Professor of Psychiatry and Clinical Sciences Vice Chair, Department of
  ...
  A. John Rush, MD, has received grant/research support from the National Institute of Mental Health and Stanley Medical Research Institute; is a consultant for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb/Otsuka, Cyberonics, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Magellan Health Services, Merck & Co, Inc, Ono Pharmaceuticals, Organon USA, Inc, Pamlab, LLC, and Pfizer Inc and is on the speakers bureau for Cyberonics, Inc, Forest Pharmaceuticals, Inc, Otsuka Pharmaceutical Group, and Pfizer Inc.

• 
  www.mentalhealthministries.net/mhm_spotlights/archives/ - [Cached Version]
  Published on: 10/1/2009    Last Visited: 10/20/2009  

  Thisquick inventory was developed by A. John Rush, MD, a leading psychiatrist and author from the University of Texas MedicalCenter. It is adapted from the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Washington,DC: American Psychiatric Association; 1994.

• 
  www.concernedcounseling.com/Communities/Depression/news - [Cached Version]
  Published on: 1/1/2006    Last Visited: 3/15/2007  

  That's pretty significant for a tough illness," said Dr. A. John Rush, a professor of psychiatry at the University of Texas Southwestern Medical Center, who led the study.
  
  But the bad news, he said, is that until patients are completely symptom-free, they risk relapse.
  
  Writing in the American Journal of Psychiatry, Rush and colleagues said their findings come from the $35 million, six-year Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, study paid for by the National Institute of Mental Health.
  ...
  Rush said only a few patients opted for cognitive therapy but his group will publish findings on that later.
  
  "Our treatments don't produce a 100 percent remission rate," he said.

• 
  www.megawang.com/bestarticles/depression/59347.php - [Cached Version]
  Published on: 7/1/2001    Last Visited: 5/11/2007  

  "The response and remission and sustained long-term benefits realized by the patients treated with adjunctive VNS Therapy is remarkable, given that participants in the trials were some of the most treatment-resistant, depressed patients ever studied, with at least half having been hospitalized for the disease at least once," commented Dr. A. John Rush, MD, Professor and Vice Chairman for Research, Department of Psychiatry, Betty Jo Hay Chair in Mental Health, Rosewood Corporation Chair in Biomedical Science, University of Texas Southwestern Medical Center, Dallas, TX. "The VNS studies presented in these publications provide substantial evidence of a growing benefit of VNS Therapy over time when other treatments have not worked or have stopped working.

• 
  www.treatment-depression.com/depression-proves-treatabl - [Cached Version]
  Last Visited: 2/9/2008  

  "It's a sobering message when you get down to requiring three or four steps," said the chief researcher, John Rush of the University of Texas Southwestern Medical Center in Dallas."It says that follow-up is critical" to make sure that people stay on the drugs, he said.

• 
  www.openminds.com/circlehome/eprint/omol/2008/091508new - [Cached Version]
  Published on: 9/15/2008    Last Visited: 9/25/2008  

  A. John Rush, M.D., Leaves University of Texas Southwestern Medical Center for Position as Vice Dean at Duke-NUS Graduate Medical School Singapore
  
  On August 26, 2008, Duke-NUS Graduate Medical School Singapore announced that Augustus John Rush, M.D., has accepted a position as vice dean for clinical sciences.Dr. Rush will live in Singapore and as vice dean will help develop education, training, and career development programs at Duke-NUS to increase the career opportunities for students seeking to become clinician-scientists.He will also work with investigators at SingHealth and other health care organizations to facilitate the development of clinical expertise and technical infrastructure support to enhance clinical research across Singapore.The Duke-NUS research programs are expected to be completed by the first quarter of 2009.The school currently operates five research programs in cancer and stem cell biology, cardiovascular and metabolic disease, emerging infectious disease, neuroscience and behavioral disorders, and health services research.
  
  Dr. Rush most recently was professor and vice chair of the Department of Clinical Sciences at the University of Texas Southwestern Medical Center.His research has been focused on the development and clinical evaluation of innovative treatments for depression, bipolar disorder, and other psychiatric disorders.He directed the STAR*D trials for depression medications.He currently directs a second depression medication trial to test the utility of medication combinations for depression.Dr. Rush was also the director of the controversial Texas Medication Algorithm Program that is now a mandatory protocol and preferred drug list for adults with mental illness.
  
  Duke-NUS was established in 2005 as a collaboration between the Duke University School of Medicine and the National University of Singapore.The school offers a graduate-entry, four-year medical program based on the Duke model of education, in which one year is dedicated to independent study and research projects.The first students started August 1, 2007.
  
  For more information, contact: A. John Rush, M.D., Vice Dean, Clinical Sciences, Duke-NUS Graduate Medical School Singapore, 2 Jalan Bukit Merah, Singapore 169547; +65-6516-7666; E-mail: info@duke-nus.edu.sg; Web site: www.duke-nus.edu.sg.
  
  A. John Rush, M.D., Leaves University of Texas Southwestern Medical Center for Position as Vice Dean at Duke-NUS Graduate Medical School Singapore. (2008, September 15).OPEN MINDS On-Line News.

• 
  psychcentral.com/news/2008/06/12/guidelines-for-clinica - [Cached Version]
  Published on: 6/13/2008    Last Visited: 6/14/2008  

  In the STAR*D project, also led by Dr. A. John Rush, professor of clinical sciences and psychiatry at UT Southwestern, only about 50 depression patients from each test-site clinic were selected to participate.

• 
  narsad.org/research/prizes/falconeprize.html - [Cached Version]
  Published on: 5/15/2008    Last Visited: 6/11/2008  

  A. John Rush, M.D. Univ. of TX Southwestern Med.Ctr. at Dallas

• 
  skorchik.eddoctor.org/2008/08/23/common-medications-pro - [Cached Version]
  Published on: 1/1/2008    Last Visited: 9/12/2008  

  "There's pious word and not-so-good news," said Dr. A. John Rush, vice chairman of clinical sciences and professor of psychiatry at UT Southwestern.

• 
  www.ahrp.org/cms/content/view/132/1/ - [Cached Version]
  Published on: 4/4/2006    Last Visited: 9/19/2009  

  All the drugs helped about 25% of people. (Effexor was slightly better, but the difference was not statistically significant.) "If insurance companies want to, I don't think there's anything wrong with them saying, 'whenever is medically reasonable, use the cheaper one," says John Rush, the UT-Southwestern psychiatrist who headed up STAR*D.

Page:  1 2 3 4 5